Dirk N.
- Country
- Germany
- Department
- Gemeinschaftsklinikum Mittelrhein gGmbH Ev. Stift St. Martin Klinik für Innere Med, Studienzentrum
Research Overview
- Randomized European Trial of Autologous Transplantation with Rituximab, Ibrutinib, and Ara-C Induction in Generalized Mantle Cell Lymphoma
- Evaluation of CPX-351 Versus Conventional Care Regimens Prior to Allogeneic Hematopoietic Cell Transplantation in High-Risk MDS and Oligoblastic AML Patients
- Evaluation of Midostaurin and Gemtuzumab Ozogamicin in Combination with Standard Induction Chemotherapy for Adult Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 68 of 218 partner sites.
Specializations
Lymphoma Research
Specializes in innovative treatments for primary CNS lymphoma and mantle cell lymphoma, with particular focus on developing therapeutic strategies involving autologous stem cell transplantation.
- Central nervous system lymphomas
- Age-adjusted treatment protocols
- High-dose chemotherapy approaches
Investigates optimized treatment combinations including rituximab-based therapies and targeted therapeutic agents.
Leukemia Treatment
Focuses on advanced therapeutic approaches for acute myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia.
- Intensive chemotherapy protocols
- Novel drug combinations
- Targeted molecular therapies
Explores innovative treatment combinations including tyrosine kinase inhibitors and immunotherapy approaches.
Stem Cell Therapeutics
Conducts research in allogeneic stem cell transplantation and autologous stem cell therapy across various hematologic conditions.
- Transplantation protocols
- High-risk myelodysplastic syndromes
- Consolidation strategies
Develops treatment protocols integrating stem cell therapy with contemporary therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.